Study of PF-07248144 in Advanced or Metastatic Solid Tumors
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This is an open-label, multi center study to evaluate safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of PF-07248144 and early signs of clinical efficacy of PF-07248144 as a single agent and in combination with other agents
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Pacjenci z rakiem piersi (ER+HER2-), rakiem prostaty lub rakiem płuca (NSCLC), który jest zaawansowany lub dał przerzuty.
- •Choroba musi być oporna lub nietolerowana na standardowe leczenie, albo nie ma dla niej standardowego leczenia.
- •W leczeniu skojarzonym, pacjentki z rakiem piersi (ER+HER2-) muszą mieć progresję choroby po leczeniu hormonalnym i inhibitorze CDK4/6.
- •Pacjenci z rakiem piersi (ER+HER2-) w drugiej linii leczenia (lub dalszych) mogą być włączeni do badania, jeśli wcześniej otrzymali leczenie inhibitorem CDK4/6 i leczenie hormonalne.
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- April 16, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (44)
HonorHealth
Scottsdale, United States
Cedars Sinai Medical Center
Los Angeles, United States
Cedars-Sinai Cancer at Cedars-Sinai Medical Center
Los Angeles, United States
UCSF Medical Center at Mission Bay
San Francisco, United States
Smilow Cancer Hospital at Yale - New Haven
New Haven, United States
Yale-New Haven Hospital- Yale Cancer Center
New Haven, United States
Smilow Cancer Hospital Phase 1 Unit
New Haven, United States
Yale University
New Haven, United States
Holy Cross Hospital
Fort Lauderdale, United States
St. Elizabeth Healthcare
Edgewood, United States
University Medical Center, lnc.:DBA University of Louisville Hospital
Louisville, United States
University of Louisville
Louisville, United States
UofL Health Brown Cancer Center
Louisville, United States
SCRI Oncology Partners
Nashville, United States
MD Anderson The Woodlands
Conroe, United States
The University of Texas M. D. Anderson Cancer Center
Houston, United States
U.T. MD Anderson Cancer Center
Houston, United States
MD Anderson West Houston
Houston, United States
MD Anderson League City
League City, United States
NEXT Oncology
San Antonio, United States
MD Anderson
Sugar Land, United States
Swedish Cancer Institute
Seattle, United States
Swedish Medical Center
Seattle, United States
Chris O'Brien Lifehouse
Camperdown, Australia
Cancer Research South Australia
Adelaide, Australia
Peter MacCallum Cancer Centre
Melbourne, Australia
Royal Melbourne Hospital
Parkville, Australia
Western Health-Sunshine & Footscray Hospitals
St Albans, Australia
St. John of God Subiaco Hospital
Subiaco, Australia
Beijing Cancer hospital
Beijing, China
SUN Yat-Sen University Cancer Center
Guangzhou, China
Jilin Province Tumor Hospital
Changchun, China
Jilin Province Tumor Hospital
Changchun, China
The First Affiliated Hospital of Xi'an Jiaotong University
Xi'an, China
Aichi Cancer Center Hospital
Nagoya, Japan
National Cancer Center Hospital East
Kashiwa, Japan
Kanagawa cancer center
Yokohama, Japan
National Cancer Center Hospital
Chuo-ku, Japan
Seoul National University Bundang Hospital
Seongnam-si, South Korea
Seoul National University Hospital
Seoul, South Korea
Severance Hospital, Yonsei University Health System
Seoul, South Korea
Samsung Medical Center
Seoul, South Korea
Kyungpook National University Chilgok Hospital
Daegu, South Korea
Asan Medical Center
Seoul, South Korea
Trial contact
Pfizer CT.gov Call Center
Contact information from ClinicalTrials.gov. Contact in English.
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/1/2026.